Mithra Pharmaceuticals Sa (MITRA)

Brussels
Currency in EUR
Disclaimer
1.18
-0.01(-0.84%)
Closed
Day's Range
1.171.21
52 wk Range
1.084.45
Prev. Close
1.19
Open
1.2
Day's Range
1.17-1.21
52 wk Range
1.08-4.45
Volume
115,493
Average Vol. (3m)
214,868
1-Year Change
-69.19%
Shares Outstanding
69,108,397
Fair Value
Unlock
Dividends Payment Streak
Unlock
Analysts
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
1.90
Upside +61.02%

People Also Watch

43.50
BEKB
+0.65%
161.50
IETB
+2.34%
27.95
EVSB
+0.36%
97.65
VGP1
-0.41%
43.85
KIPO
-0.90%
How do you feel today about MITRA?
Vote to see community's results!
or

Mithra Pharmaceuticals Sa Company Profile

Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Belgium, Europe and internationally. Its development candidates include Estelle, a combined oral contraceptive that has completed phase III clinical trial; Donesta, which is in phase III clinical trial for estetrol-based oral hormone treatment; and products for neuroprotection and wound healing. The company also develops Myring, a contraceptive vaginal ring releasing a combination of hormones; Tibelia, a tablet composed of tibolone and a synthetic steroid used for hormone therapy in menopause; and Zoreline, a biodegradable subcutaneous implant for use in prostate and breast cancers, and benign gynecological indications. In addition, it provides products in polymeric forms, implants, sterile injectable products, and hormonal tablets. The company was founded in 1999 and is headquartered in Liège, Belgium.

Employees
229
Market
Belgium